ROIV
Roivant Sciences Ltd.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Roivant Sciences Ltd.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Roivant Sciences has 4 disclosed suppliers and 2 disclosed customers in SEC filings.
Roivant Sciences Ltd.
36.66
Sentence• Mosliciguat (Pulmovant): up to a maximum of $280.0 million to Bayer upon the achievement of certain development, regulatory and commercial milestone events and tiered high-single-digits royalty on net sales.
ROIV 10-Kaccession 0001635088-26-000061
SentenceOur subsidiary Immunovant holds the intellectual property rights to IMVT-1402 and batoclimab under a license agreement with HanAll Biopharma Co., Ltd. ("HanAll") (the "HanAll Agreement").
ROIV 10-Kaccession 0001635088-26-000061
Sentence• Brepocitinib (Priovant) : mid tens-of-millions sales milestone payment to Pfizer if aggregate net sales in a given year exceed a mid-hundreds-of-millions amount and tiered sub-teens royalty on net sales.
ROIV 10-Kaccession 0001635088-26-000061
SentenceDuring the year ended March 31, 2025, we repurchased 128,361,786 shares for an aggregate purchase price of approximately $1.3 billion (including fees and expenses), including 71,251,083 shares repurchased from Sumitomo Pharma Co., Ltd. at $9.10 per share for approximately $648.4 million.
ROIV 10-Kaccession 0001635088-26-000061
In August 2023, we completed a transaction with SK Biopharmaceuticals Co., Ltd. ("SK Bio"), a subsidiary of SK, Inc., pursuant to which SK Bio purchased all of our shares in Proteovant in exchange for $47.5 million .
ROIV 10-Kaccession 0001635088-26-000061
Largest filed tie
—
Expected move
Inputs8Q avg ±6.6%·×1.44·rich
straddle ±10.6%
spot 36.91exp Nov 20ATM strike 37ATM straddle 4.60IV 65%